What changed: Non-small cell lung cancer
Every dated change on the records linked to Non-small cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
April 2026 · 1
2026 · 2
- 2026ApprovalTechnetium (99mTc) pexiretideTechnetium (99mTc) pexiretide approved in China
SPECT/CT assessment of regional lymph-node metastasis in patients with suspected lung cancer
- 2026MilestoneTechnetium (99mTc) pexiretideChina approves technetium (99mTc) pexiretide for nodal staging
NMPA approval on 2 April 2026 of an integrin alpha-v-beta-3 RGD peptide for SPECT/CT assessment of regional lymph nodes in suspected lung cancer.
February 2025 · 1
2025 · 1
2021 · 2
- 2021GuidelineNon-small cell lung cancerGuideline USPSTF final recommendation statement, 9 March 2021: Screening in people at risk
Annual low-dose CT for adults aged 50 to 80 with a 20 pack-year smoking history who still smoke or quit within the past 15 years; stopped after 15 smoke-free years or when a competing health problem limits benefit.
- 2021MilestoneNon-small cell lung cancerUSPSTF widens low-dose CT screening
Final statement of 9 March 2021: annual LDCT for adults aged 50 to 80 with a 20 pack-year history who smoke or quit within 15 years, lowering both the age and pack-year thresholds.